6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
7%	CD	7%	7%	7%	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
UCB	NNP	ucb	ucb	ucb	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
866	CD	866	866	866	N	O
-	:	-	-	-	N	O
822	CD	822	822	822	N	O
-	:	-	-	-	N	O
0068	CD	0068	0068	0068	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Heart	NNP	heart	heart	heart	N	B-AdverseReaction
Failure	NNP	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
and	CC	and	and	and	N	O
controlled	JJ	controlled	controlled	control	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
predict	VB	predict	predict	predict	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
broader	JJR	broader	broader	broader	N	O
patient	JJ	patient	patient	patient	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

premarketing	VBG	premarketing	premarketing	premarket	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
patient	JJ	patient	patient	patient	N	O
populations	NNS	populations	population	popul	N	O
combined	VBN	combined	combined	combin	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Most	JJS	most	most	most	N	O
Commonly	RB	commonly	commonly	commonli	N	O
Leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
Premarketing	NNP	premarketing	premarketing	premarket	N	O
Controlled	NNP	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
8%	CD	8%	8%	8%	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
0%	CD	0%	0%	0%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
obstruction	NN	obstruction	obstruction	obstruct	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
0%	CD	0%	0%	0%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rheumatoid	JJ	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
were	VBD	were	were	were	N	O
tuberculosis	JJ	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
pyrexia	VB	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Controlled	VBN	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
Disease	NNP	disease	disease	diseas	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
at	IN	at	at	at	N	O
400	CD	400	400	400	N	O
mg	NNS	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
dosing	VBG	dosing	dosing	dose	N	O
in	IN	in	in	in	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
620	CD	620	620	620	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
received	VBD	received	received	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
614	CD	614	614	614	N	O
subjects	NNS	subjects	subject	subject	N	O
received	VBN	received	received	receiv	N	O
placebo	NNS	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
CD2	NNP	cd2	cd2	cd2	N	O
following	VBG	following	following	follow	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
dosing	NN	dosing	dosing	dose	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
at	IN	at	at	at	N	O
Weeks	NNP	weeks	week	week	N	O
0	CD	0	0	0	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
564	CD	564	564	564	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
at	IN	at	at	at	N	O
some	DT	some	some	some	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
350	CD	350	350	350	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
55%	CD	55%	55%	55%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
,	,	,	,	,	N	O
45%	CD	45%	45%	45%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
94%	CD	94%	94%	94%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
group	NN	group	group	group	N	O
were	VBD	were	were	were	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
ages	NNS	ages	age	age	N	O
of	IN	of	of	of	N	O
18	CD	18	18	18	N	O
and	CC	and	and	and	N	O
64	CD	64	64	64	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
9%	CD	9%	9%	9%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
were	VBD	were	were	were	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
laryngitis	NN	laryngitis	laryngitis	laryng	Y	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

bladder	NN	bladder	bladder	bladder	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
bacteriuria	NN	bacteriuria	bacteriuria	bacteriuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
4%	CD	4%	4%	4%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	JJ	commonly	commonly	commonli	N	O
occurring	VBG	occurring	occurring	occur	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
were	VBD	were	were	were	N	O
described	VBN	described	described	describ	N	O
above	IN	above	above	abov	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
or	CC	or	or	or	N	O
significant	JJ	significant	significant	signific	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
diseases	NNS	diseases	disease	diseas	N	O
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
400	CD	400	400	400	N	O
mg	NNS	mg	mg	mg	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
doses	NNS	doses	dos	dose	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombophilia	NNS	thrombophilia	thrombophilia	thrombophilia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Angina	NNP	angina	angina	angina	N	B-AdverseReaction
pectoris	NN	pectoris	pectoris	pectori	N	I-AdverseReaction
,	,	,	,	,	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	B-AdverseReaction
,	,	,	,	,	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
ischemia	NN	ischemia	ischemia	ischemia	Y	I-AdverseReaction
,	,	,	,	,	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
,	,	,	,	,	N	O
pericarditis	NN	pericarditis	pericarditis	pericard	Y	B-AdverseReaction
,	,	,	,	,	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
and	CC	and	and	and	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
.	.	.	.	.	N	O

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Optic	JJ	optic	optic	optic	N	B-AdverseReaction
neuritis	NN	neuritis	neuritis	neuriti	Y	I-AdverseReaction
,	,	,	,	,	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	B-AdverseReaction
.	.	.	.	.	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
and	CC	and	and	and	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
totalis	NN	totalis	totalis	totali	N	I-AdverseReaction
.	.	.	.	.	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
,	,	,	,	,	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
suicide	JJ	suicide	suicide	suicid	Y	B-AdverseReaction
attempt	NN	attempt	attempt	attempt	N	I-AdverseReaction
.	.	.	.	.	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Nephrotic	JJ	nephrotic	nephrotic	nephrot	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
system	NN	system	system	system	N	O
and	CC	and	and	and	N	O
breast	NN	breast	breast	breast	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Menstrual	JJ	menstrual	menstrual	menstrual	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
nodosum	NN	nodosum	nodosum	nodosum	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Thrombophlebitis	NN	thrombophlebitis	thrombophlebitis	thrombophleb	Y	B-AdverseReaction
,	,	,	,	,	N	O
vasculitis	NN	vasculitis	vasculitis	vascul	Y	B-AdverseReaction
.	.	.	.	.	N	O

Controlled	VBN	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
Rheumatoid	NNP	rheumatoid	rheumatoid	rheumatoid	N	O
Arthritis	NNP	arthritis	arthritis	arthriti	Y	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
primarily	RB	primarily	primarily	primarili	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
follow	SYM	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
367	CD	367	367	367	N	O
RA	NNP	ra	ra	ra	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
030	CD	030	030	030	N	O
exposed	VBN	exposed	exposed	expos	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
663	CD	663	663	663	N	O
exposed	VBN	exposed	exposed	expos	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
and	CC	and	and	and	N	O
282	CD	282	282	282	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
774	CD	774	774	774	N	O
in	IN	in	in	in	N	O
adequate	NN	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
53	CD	53	53	53	N	O
years	NNS	years	year	year	N	O
at	IN	at	at	at	N	O
entry	NN	entry	entry	entri	N	O
;	:	;	;	;	N	O
approximately	RB	approximately	approximately	approxim	N	O
80%	CD	80%	80%	80%	N	O
were	VBD	were	were	were	N	O
females	NNS	females	female	femal	N	O
,	,	,	,	,	N	O
93%	CD	93%	93%	93%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
suffering	VBG	suffering	suffering	suffer	N	O
from	IN	from	from	from	N	O
active	JJ	active	active	activ	N	O
rheumatoid	NN	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
disease	NN	disease	disease	diseas	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
6.2	CD	6.2	6.2	6.2	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3%	CD	3%	3%	3%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
saline	JJ	saline	saline	salin	N	O
formulation	NN	formulation	formulation	formul	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
given	VBN	given	given	given	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
Dosed	VBD	dosed	dosed	dose	N	O
Every	DT	every	every	everi	N	O
Other	JJ	other	other	other	N	O
Week	NNP	week	week	week	N	O
during	IN	during	during	dure	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Period	NNP	period	period	period	N	O
of	IN	of	of	of	N	O
Rheumatoid	NNP	rheumatoid	rheumatoid	rheumatoid	N	O
Arthritis	NNP	arthritis	arthritis	arthriti	Y	O
Studies	NNP	studies	study	studi	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Methotrexate	NNP	methotrexate	methotrexate	methotrex	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
MTX	NNP	mtx	mtx	mtx	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
324	CD	324	324	324	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
EOW	NNP	eow	eow	eow	N	O
MTX	NNP	mtx	mtx	mtx	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
640	CD	640	640	640	N	O

Upper	IN	upper	upper	upper	N	B-AdverseReaction

respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
2	CD	2	2	2	N	O
6	CD	6	6	6	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
1	CD	1	1	1	N	O
5	CD	5	5	5	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
bronchitis	VBD	bronchitis	bronchitis	bronchiti	Y	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
controls	NNS	controls	control	control	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
baseline	JJ	baseline	baseline	baselin	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
and	CC	and	and	and	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
steroidal	NN	steroidal	steroidal	steroid	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O

receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
every	DT	every	every	everi	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
in	IN	in	in	in	N	O
rheumatoid	JJ	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
had	VBD	had	had	had	N	O
similar	JJ	similar	similar	similar	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Other	JJ	other	other	other	N	O
infrequent	JJ	infrequent	infrequent	infrequ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
RA	NNP	ra	ra	ra	Y	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
Arthritis	NNP	arthritis	arthritis	arthriti	Y	O
Clinical	NNP	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
409	CD	409	409	409	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
psoriatic	JJ	psoriatic	psoriatic	psoriat	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
(	(	(	(	(	N	O
PsA	NNP	psa	psa	psa	Y	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PsA	NNP	psa	psa	psa	Y	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
and	CC	and	and	and	N	O
previous	JJ	previous	previous	previou	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

Ankylosing	VBG	ankylosing	ankylosing	ankylos	N	O
Spondylitis	NNP	spondylitis	spondylitis	spondyl	Y	O
Clinical	NNP	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
325	CD	325	325	325	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
axial	JJ	axial	axial	axial	N	O
spondyloarthritis	NN	spondyloarthritis	spondyloarthritis	spondyloarthr	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
had	VBD	had	had	had	N	O
ankylosing	VBG	ankylosing	ankylosing	ankylos	N	O
spondylitis	NN	spondylitis	spondylitis	spondyl	Y	O
(	(	(	(	(	N	O
AS	NNP	as	a	as	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
(	(	(	(	(	N	O
AS	IN	as	a	as	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
study	NN	study	study	studi	N	O
AS	IN	as	a	as	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
was	VBD	was	wa	wa	N	O
38%	CD	38%	38%	38%	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
30%	CD	30%	30%	30%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
consisted	VBD	consisted	consisted	consist	N	O
primarily	RB	primarily	primarily	primarili	N	O
of	IN	of	of	of	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
13%	CD	13%	13%	13%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
3%	CD	3%	3%	3%	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
observed	VBD	observed	observed	observ	N	O
included	JJ	included	included	includ	N	O
bacterial	NN	bacterial	bacterial	bacteri	N	B-AdverseReaction
and	CC	and	and	and	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyelonephritis	NN	pyelonephritis	pyelonephritis	pyelonephr	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
rheumatoid	JJ	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
was	VBD	was	wa	wa	N	O
0.91	CD	0.91	0.91	0.91	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0.72	CD	0.72	0.72	0.72	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
consisted	VBD	consisted	consisted	consist	N	O
primarily	RB	primarily	primarily	primarili	N	O
of	IN	of	of	of	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
rheumatoid	NN	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
new	JJ	new	new	new	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infection	NN	infection	infection	infect	Y	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
groups	NNS	groups	group	group	N	O
(	(	(	(	(	N	O
0.06	CD	0.06	0.06	0.06	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
doses	VBZ	doses	dos	dose	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.02	CD	0.02	0.02	0.02	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
dose	JJ	dose	dose	dose	N	O
group	NN	group	group	group	N	O
were	VBD	were	were	were	N	O
0.06	CD	0.06	0.06	0.06	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
every	DT	every	every	everi	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
dose	JJ	dose	dose	dose	N	O
group	NN	group	group	group	N	O
were	VBD	were	were	were	N	O
0.04	CD	0.04	0.04	0.04	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
included	VBD	included	included	includ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyelonephritis	NN	pyelonephritis	pyelonephritis	pyelonephr	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infection	NN	infection	infection	infect	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
subject	NN	subject	subject	subject	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	O
with	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
exposure	NN	exposure	exposure	exposur	N	O
over	IN	over	over	over	N	O
time	NN	time	time	time	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
and	CC	and	and	and	N	O
Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
Infections	NNS	infections	infection	infect	N	O

In	IN	in	in	in	N	O
completed	VBN	completed	completed	complet	N	O
and	CC	and	and	and	N	O
ongoing	VBG	ongoing	ongoing	ongo	N	O
global	JJ	global	global	global	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
indications	NNS	indications	indication	indic	N	O
including	VBG	including	including	includ	N	O
5	CD	5	5	5	N	O
,	,	,	,	,	N	O
118	CD	118	118	118	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
approximately	RB	approximately	approximately	approxim	N	O
0.61	CD	0.61	0.61	0.61	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
indications	NNS	indications	indication	indic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
countries	NNS	countries	country	countri	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
endemic	JJ	endemic	endemic	endem	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
.	.	.	.	.	N	O

Reports	NNS	reports	report	report	N	O
include	VBP	include	include	includ	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
miliary	JJ	miliary	miliary	miliari	N	B-AdverseReaction
,	,	,	,	,	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	B-AdverseReaction
,	,	,	,	,	N	O
peritoneal	JJ	peritoneal	peritoneal	periton	N	B-AdverseReaction
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
TB	NNP	tb	tb	tb	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
indications	NNS	indications	indication	indic	N	O
was	VBD	was	wa	wa	N	O
345	CD	345	345	345	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
RA	NNP	ra	ra	ra	Y	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
36	CD	36	36	36	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
among	IN	among	among	among	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
367	CD	367	367	367	N	O
exposed	VBD	exposed	exposed	expos	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
some	DT	some	some	some	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
.	.	.	.	.	N	O

Rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
and	CC	and	and	and	N	O
control	NN	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
some	DT	some	some	some	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
more	JJR	more	more	more	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
those	DT	those	those	those	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
control	VB	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Heart	NNP	heart	heart	heart	N	O
Failure	NN	failure	failure	failur	N	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
rheumatoid	NN	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	B-AdverseReaction
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
mild	JJ	mild	mild	mild	N	O
to	TO	to	to	to	N	O
moderate	VB	moderate	moderate	moder	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
year	NN	year	year	year	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Autoantibodies	NNS	autoantibodies	autoantibody	autoantibodi	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
that	WDT	that	that	that	N	O
had	VBD	had	had	had	N	O
negative	JJ	negative	negative	neg	N	O
baseline	NN	baseline	baseline	baselin	N	O
ANA	NNP	ana	ana	ana	Y	B-AdverseReaction
titers	NNS	titers	titer	titer	N	I-AdverseReaction
developed	VBD	developed	developed	develop	N	O
positive	JJ	positive	positive	posit	N	I-AdverseReaction
titers	NNS	titers	titer	titer	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
564	CD	564	564	564	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
developed	VBD	developed	developed	develop	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
lupus	JJ	lupus	lupus	lupu	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
developed	VBN	developed	developed	develop	N	O
ANA	NNP	ana	ana	ana	Y	B-AdverseReaction
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
patients	NNS	patients	patient	patient	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
367	CD	367	367	367	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
RA	NNP	ra	ra	ra	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
developed	VBD	developed	developed	develop	N	O
clinical	JJ	clinical	clinical	clinic	N	O
signs	NNS	signs	sign	sign	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
lupus	JJ	lupus	lupus	lupu	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
impact	NN	impact	impact	impact	N	O
of	IN	of	of	of	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
autoimmune	NN	autoimmune	autoimmune	autoimmun	N	O
diseases	NNS	diseases	disease	diseas	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
tested	VBN	tested	tested	test	N	O
at	IN	at	at	at	N	O
multiple	JJ	multiple	multiple	multipl	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
certolizumab	VB	certolizumab	certolizumab	certolizumab	N	O
pegol	NN	pegol	pegol	pegol	N	O
during	IN	during	during	dure	N	O
Studies	NNPS	studies	study	studi	N	O
CD1	NNP	cd1	cd1	cd1	N	O
and	CC	and	and	and	N	O
CD2	NNP	cd2	cd2	cd2	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positive	JJ	positive	positive	posit	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
8%	CD	8%	8%	8%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
continuously	RB	continuously	continuously	continu	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
6%	CD	6%	6%	6%	N	O
were	VBD	were	were	were	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
apparent	JJ	apparent	apparent	appar	N	O
correlation	NN	correlation	correlation	correl	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
or	CC	or	or	or	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
not	RB	not	not	not	N	O
taking	VBG	taking	taking	take	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
11%	CD	11%	11%	11%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
antibody	JJ	antibody	antibody	antibodi	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
100	CD	100	100	100	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3%	CD	3%	3%	3%	N	O
higher	JJR	higher	higher	higher	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
antibody	VB	antibody	antibody	antibodi	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
242	CD	242	242	242	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	JJ	edema	edema	edema	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
nodosum	NN	nodosum	nodosum	nodosum	N	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
certolizumab	VB	certolizumab	certolizumab	certolizumab	N	O
pegol	NN	pegol	pegol	pegol	N	O
detectable	JJ	detectable	detectable	detect	N	O
on	IN	on	on	on	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
occasion	NN	occasion	occasion	occas	N	O
was	VBD	was	wa	wa	N	O
7%	CD	7%	7%	7%	N	O
(	(	(	(	(	N	O
105	CD	105	105	105	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
509	CD	509	509	509	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
rheumatoid	NN	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
third	JJ	third	third	third	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
,	,	,	,	,	N	O
39	CD	39	39	39	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
509	CD	509	509	509	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
with	IN	with	with	with	N	O
neutralizing	JJ	neutralizing	neutralizing	neutral	N	O
activity	NN	activity	activity	activ	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
(	(	(	(	(	N	O
MTX	NNP	mtx	mtx	mtx	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
not	RB	not	not	not	N	O
taking	VBG	taking	taking	take	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
MTX	NNP	mtx	mtx	mtx	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
,	,	,	,	,	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
II	NNP	ii	ii	ii	N	O
,	,	,	,	,	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
III	NNP	iii	iii	iii	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
overall	JJ	overall	overall	overal	N	O
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
in	IN	in	in	in	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
IV	NNP	iv	iv	iv	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Both	DT	both	both	both	N	O
the	DT	the	the	the	N	O
loading	NN	loading	loading	load	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
400	CD	400	400	400	N	O
mg	NNS	mg	mg	mg	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
at	IN	at	at	at	N	O
Weeks	NNP	weeks	week	week	N	O
0	CD	0	0	0	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
and	CC	and	and	and	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
MTX	NNP	mtx	mtx	mtx	N	O
were	VBD	were	were	were	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
reduced	JJ	reduced	reduced	reduc	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

Antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
lowered	JJ	lowered	lowered	lower	N	O
drug	NN	drug	drug	drug	N	O
plasma	NN	plasma	plasma	plasma	N	O
concentration	NN	concentration	concentration	concentr	N	O
and	CC	and	and	and	N	O
reduced	JJ	reduced	reduced	reduc	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
dosage	NN	dosage	dosage	dosag	N	O
of	IN	of	of	of	N	O
200	CD	200	200	200	N	O
mg	NNS	mg	mg	mg	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
MTX	NNP	mtx	mtx	mtx	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
ACR20	NNP	acr20	acr20	acr20	N	O
response	NN	response	response	respons	N	O
was	VBD	was	wa	wa	N	O
lower	JJR	lower	lower	lower	N	O
among	IN	among	among	among	N	O
antibody	JJ	antibody	antibody	antibodi	N	O
positive	JJ	positive	positive	posit	N	O
patients	NNS	patients	patient	patient	N	O
than	IN	than	than	than	N	O
among	IN	among	among	among	N	O
antibody	JJ	antibody	antibody	antibodi	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
,	,	,	,	,	N	O
48%	CD	48%	48%	48%	N	O
versus	NN	versus	versus	versu	N	O
60%	CD	60%	60%	60%	N	O
;	:	;	;	;	N	O
Study	NNP	study	study	studi	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
II	VBZ	ii	ii	ii	N	O
35%	CD	35%	35%	35%	N	O
versus	NN	versus	versus	versu	N	O
59%	CD	59%	59%	59%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
III	NN	iii	iii	iii	N	O
,	,	,	,	,	N	O
too	RB	too	too	too	N	O
few	JJ	few	few	few	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
allow	VB	allow	allow	allow	N	O
for	IN	for	for	for	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
ACR20	NNP	acr20	acr20	acr20	N	O
response	NN	response	response	respons	N	O
by	IN	by	by	by	N	O
antibody	NN	antibody	antibody	antibodi	N	O
status	NN	status	status	statu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
RA	NNP	ra	ra	ra	Y	O
-	:	-	-	-	N	O
IV	NNP	iv	iv	iv	N	O
(	(	(	(	(	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
ACR20	NNP	acr20	acr20	acr20	N	O
response	NN	response	response	respons	N	O
was	VBD	was	wa	wa	N	O
33%	CD	33%	33%	33%	N	O
versus	NN	versus	versus	versu	N	O
56%	CD	56%	56%	56%	N	O
,	,	,	,	,	N	O
antibody	NN	antibody	antibody	antibodi	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
versus	NN	versus	versus	versu	N	O
antibody	NN	antibody	antibody	antibodi	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
status	NN	status	status	statu	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
association	NN	association	association	associ	N	O
was	VBD	was	wa	wa	N	O
seen	VBN	seen	seen	seen	N	O
between	IN	between	between	between	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
test	NN	test	test	test	N	O
results	NNS	results	result	result	N	O
were	VBD	were	were	were	N	O
considered	VBN	considered	considered	consid	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
certolizumab	VB	certolizumab	certolizumab	certolizumab	N	O
pegol	NN	pegol	pegol	pegol	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
ELISA	NNP	elisa	elisa	elisa	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
,	,	,	,	,	N	O
assay	VBP	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
certolizumab	VB	certolizumab	certolizumab	certolizumab	N	O
pegol	NN	pegol	pegol	pegol	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
compatible	JJ	compatible	compatible	compat	N	O
with	IN	with	with	with	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
rarely	RB	rarely	rarely	rare	N	O
following	VBG	following	following	follow	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
administration	NN	administration	administration	administr	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
allergic	NN	allergic	allergic	allerg	N	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
postural	JJ	postural	postural	postur	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dyspnea	UH	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hot	JJ	hot	hot	hot	N	B-AdverseReaction
flush	NN	flush	flush	flush	N	I-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
serum	NN	serum	serum	serum	N	B-AdverseReaction
sickness	NN	sickness	sickness	sick	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
vasovagal	NN	vasovagal	vasovagal	vasovag	N	B-AdverseReaction
)	)	)	)	)	N	O
syncope	NN	syncope	syncope	syncop	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
estimate	VB	estimate	estimate	estim	N	O
reliably	RB	reliably	reliably	reliabl	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorder	NN	disorder	disorder	disord	N	O
:	:	:	:	:	N	O
systemic	JJ	systemic	systemic	system	N	B-AdverseReaction
vasculitis	NN	vasculitis	vasculitis	vascul	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
.	.	.	.	.	N	O

Skin	NN	skin	skin	skin	N	O
:	:	:	:	:	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
,	,	,	,	,	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	B-AdverseReaction
(	(	(	(	(	N	O
all	DT	all	all	all	N	O
sub	VBP	sub	sub	sub	N	O
-	:	-	-	-	N	O
types	NNS	types	type	type	N	O
including	VBG	including	including	includ	N	O
pustular	NN	pustular	pustular	pustular	N	I-AdverseReaction
and	CC	and	and	and	N	O
palmoplantar	NN	palmoplantar	palmoplantar	palmoplantar	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
sarcoidosis	NN	sarcoidosis	sarcoidosis	sarcoidosi	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
SERIOUS	JJ	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
MALIGNANCY	NNP	malignancy	malignancy	malign	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
SERIOUS	JJ	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
MALIGNANCY	NNP	malignancy	malignancy	malign	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
SERIOUS	NNP	serious	serious	seriou	N	O
INFECTIONS	NNP	infections	infection	infect	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Patients	NNP	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
these	DT	these	these	these	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
or	CC	or	or	or	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	O
.	.	.	.	.	N	O

Reported	VBN	reported	reported	report	N	O
infections	NNS	infections	infection	infect	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Active	NNP	active	active	activ	N	B-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
latent	JJ	latent	latent	latent	N	I-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
frequently	RB	frequently	frequently	frequent	N	O
presented	VBN	presented	presented	present	N	O
with	IN	with	with	with	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	I-AdverseReaction
or	CC	or	or	or	N	O
extrapulmonary	JJ	extrapulmonary	extrapulmonary	extrapulmonari	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
before	IN	before	before	befor	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
infection	NN	infection	infection	infect	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
coccidioidomycosis	NN	coccidioidomycosis	coccidioidomycosis	coccidioidomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
blastomycosis	NN	blastomycosis	blastomycosis	blastomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumocystosis	NN	pneumocystosis	pneumocystosis	pneumocystosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
present	VB	present	present	present	N	O
with	IN	with	with	with	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	I-AdverseReaction
,	,	,	,	,	N	O
rather	RB	rather	rather	rather	N	O
than	IN	than	than	than	N	O
localized	JJ	localized	localized	local	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Antigen	NNP	antigen	antigen	antigen	N	O
and	CC	and	and	and	N	O
antibody	NN	antibody	antibody	antibodi	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
negative	JJ	negative	negative	neg	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Empiric	NNP	empiric	empiric	empir	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
fungal	JJ	fungal	fungal	fungal	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infections	NNS	infections	infection	infect	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
severe	JJ	severe	severe	sever	N	O
systemic	JJ	systemic	systemic	system	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Bacterial	NNP	bacterial	bacterial	bacteri	N	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
infections	NNS	infections	infection	infect	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
pathogens	NNS	pathogens	pathogen	pathogen	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Legionella	NNP	legionella	legionella	legionella	N	I-AdverseReaction
and	CC	and	and	and	N	O
Listeria	NNP	listeria	listeria	listeria	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
considered	VBN	considered	considered	consid	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
or	CC	or	or	or	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

MALIGNANCY	NNP	malignancy	malignancy	malign	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
SERIOUS	JJ	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
MALIGNANCY	NNP	malignancy	malignancy	malign	N	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
TB	NNP	tb	tb	tb	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
sepsis	NN	sepsis	sepsis	sepsi	Y	I-AdverseReaction
,	,	,	,	,	N	O
invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
due	JJ	due	due	due	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
other	JJ	other	other	other	N	I-AdverseReaction
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	I-AdverseReaction
pathogens	NNS	pathogens	pathogen	pathogen	N	I-AdverseReaction
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Perform	NNP	perform	perform	perform	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
TB	NNP	tb	tb	tb	Y	O
;	:	;	;	;	N	O
if	IN	if	if	if	N	O
positive	JJ	positive	positive	posit	N	O
,	,	,	,	,	N	O
start	JJ	start	start	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
TB	NNP	tb	tb	tb	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
starting	VBG	starting	starting	start	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
active	JJ	active	active	activ	N	O
TB	NNP	tb	tb	tb	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
if	IN	if	if	if	N	O
initial	JJ	initial	initial	initi	N	O
latent	NN	latent	latent	latent	N	O
TB	NNP	tb	tb	tb	Y	O
test	NN	test	test	test	N	O
is	VBZ	is	is	is	N	O
negative	JJ	negative	negative	neg	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
8.4	CD	8.4	8.4	8.4	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
-	:	-	-	-	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
start	VB	start	start	start	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
during	IN	during	during	dure	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
an	DT	an	an	an	N	O
infection	NN	infection	infection	infect	Y	O
develops	VBZ	develops	develops	develop	N	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
carefully	RB	carefully	carefully	care	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
stop	VB	stop	stop	stop	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
if	IN	if	if	if	N	O
infection	NN	infection	infection	infect	Y	O
becomes	VBZ	becomes	becomes	becom	N	O
serious	JJ	serious	serious	seriou	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
-	:	-	-	-	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
systemic	JJ	systemic	systemic	system	N	O
illness	NN	illness	illness	ill	N	O
on	IN	on	on	on	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
empiric	JJ	empiric	empiric	empir	N	O
antifungal	NN	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
reside	VBP	reside	reside	resid	N	O
or	CC	or	or	or	N	O
travel	VBP	travel	travel	travel	N	O
to	TO	to	to	to	N	O
regions	NNS	regions	region	region	N	O
where	WRB	where	where	where	N	O
mycoses	NNS	mycoses	mycoses	mycos	N	O
are	VBP	are	are	are	N	O
endemic	JJ	endemic	endemic	endem	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Heart	NNP	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
worsening	VBG	worsening	worsening	worsen	N	I-AdverseReaction
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	I-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
reactivation	NN	reactivation	reactivation	reactiv	N	I-AdverseReaction
-	:	-	-	-	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
HBV	NNP	hbv	hbv	hbv	N	O
carriers	NNS	carriers	carrier	carrier	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
stop	VB	stop	stop	stop	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
begin	VB	begin	begin	begin	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
viral	JJ	viral	viral	viral	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Demyelinating	VBG	demyelinating	demyelinating	demyelin	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	O
onset	NN	onset	onset	onset	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Cytopenias	NNP	cytopenias	cytopenia	cytopenia	N	B-AdverseReaction
,	,	,	,	,	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
-	:	-	-	-	N	O
advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
if	IN	if	if	if	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
develop	VBP	develop	develop	develop	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
stopping	VBG	stopping	stopping	stop	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Lupus	NNP	lupus	lupus	lupu	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
syndrome	JJ	syndrome	syndrome	syndrom	N	I-AdverseReaction
-	:	-	-	-	N	O
stop	NN	stop	stop	stop	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
if	IN	if	if	if	N	O
syndrome	JJ	syndrome	syndrome	syndrom	N	O
develops	NNS	develops	develops	develop	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Risk	NN	risk	risk	risk	N	O

of	IN	of	of	of	N	O
Serious	JJ	serious	serious	seriou	N	O
Infections	NNS	infections	infection	infect	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NN	]	]	]	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
involving	VBG	involving	involving	involv	N	O
various	JJ	various	various	variou	N	O
organ	JJ	organ	organ	organ	N	O
systems	NNS	systems	system	system	N	O
and	CC	and	and	and	N	O
sites	NNS	sites	site	site	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	I-AdverseReaction
,	,	,	,	,	N	O
mycobacterial	JJ	mycobacterial	mycobacterial	mycobacteri	N	I-AdverseReaction
,	,	,	,	,	N	O
invasive	JJ	invasive	invasive	invas	N	I-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	I-AdverseReaction
,	,	,	,	,	N	O
parasitic	JJ	parasitic	parasitic	parasit	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
pathogens	NNS	pathogens	pathogen	pathogen	N	O
including	VBG	including	including	includ	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
blastomycosis	NN	blastomycosis	blastomycosis	blastomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
coccidioidomycosis	NN	coccidioidomycosis	coccidioidomycosis	coccidioidomycosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
legionellosis	NN	legionellosis	legionellosis	legionellosi	N	B-AdverseReaction
,	,	,	,	,	N	O
listeriosis	NN	listeriosis	listeriosis	listeriosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumocystosis	NN	pneumocystosis	pneumocystosis	pneumocystosi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
frequently	RB	frequently	frequently	frequent	N	O
presented	VBN	presented	presented	present	N	O
with	IN	with	with	with	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	O
rather	RB	rather	rather	rather	N	O
than	IN	than	than	than	N	O
localized	JJ	localized	localized	local	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
clinically	RB	clinically	clinically	clinic	N	O
important	JJ	important	important	import	N	O
localized	VBN	localized	localized	local	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
morbid	NN	morbid	morbid	morbid	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O

with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
or	CC	or	or	or	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
infection	NN	infection	infection	infect	Y	O

who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
tuberculosis	VB	tuberculosis	tuberculosis	tuberculosi	Y	O

with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
infection	NN	infection	infection	infect	Y	O

who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
resided	VBN	resided	resided	resid	N	O
or	CC	or	or	or	N	O
traveled	VBN	traveled	traveled	travel	N	O
in	IN	in	in	in	N	O
areas	NNS	areas	area	area	N	O
of	IN	of	of	of	N	O
endemic	JJ	endemic	endemic	endem	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
or	CC	or	or	or	N	O
endemic	JJ	endemic	endemic	endem	N	O
mycoses	NNS	mycoses	mycoses	mycos	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
,	,	,	,	,	N	O
coccidioidomycosis	NN	coccidioidomycosis	coccidioidomycosis	coccidioidomycosi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
blastomycosis	NN	blastomycosis	blastomycosis	blastomycosi	Y	O

with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
infection	VB	infection	infection	infect	Y	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O

Cases	NNS	cases	case	case	N	O

of	IN	of	of	of	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
previously	RB	previously	previously	previous	N	O
received	VBN	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	NN	latent	latent	latent	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
and	CC	and	and	and	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocking	VBG	blocking	blocking	block	N	O
agents	NNS	agents	agent	agent	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Induration	NN	induration	induration	indur	Y	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mm	NN	mm	mm	mm	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
with	IN	with	with	with	N	O
tuberculin	NN	tuberculin	tuberculin	tuberculin	N	O
skin	NN	skin	skin	skin	N	O
testing	NN	testing	testing	test	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
positive	JJ	positive	positive	posit	N	O
test	NN	test	test	test	N	O
result	NN	result	result	result	N	O
when	WRB	when	when	when	N	O
assessing	VBG	assessing	assessing	assess	N	O
if	IN	if	if	if	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
previously	RB	previously	previously	previous	N	O
vaccinated	VBN	vaccinated	vaccinated	vaccin	N	O
with	IN	with	with	with	N	O
Bacille	NNP	bacille	bacille	bacil	N	O
Calmette	NNP	calmette	calmette	calmett	N	O
-	:	-	-	-	N	O
Guerin	NNP	guerin	guerin	guerin	N	O
(	(	(	(	(	N	O
BCG	NNP	bcg	bcg	bcg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Anti	NNP	anti	anti	anti	N	O
-	:	-	-	-	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
past	JJ	past	past	past	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
latent	NN	latent	latent	latent	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
an	DT	an	an	an	N	O
adequate	JJ	adequate	adequate	adequ	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
negative	JJ	negative	negative	neg	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
but	CC	but	but	but	N	O
having	VBG	having	having	have	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
with	IN	with	with	with	N	O
expertise	NN	expertise	expertise	expertis	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
to	TO	to	to	to	N	O
aid	NN	aid	aid	aid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
decision	NN	decision	decision	decis	N	O
of	IN	of	of	of	N	O
whether	IN	whether	whether	whether	N	O
initiating	VBG	initiating	initiating	initi	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
individual	JJ	individual	individual	individu	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
strongly	RB	strongly	strongly	strongli	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
previously	RB	previously	previously	previous	N	O
or	CC	or	or	or	N	O
recently	RB	recently	recently	recent	N	O
traveled	VBD	traveled	traveled	travel	N	O
to	TO	to	to	to	N	O
countries	NNS	countries	country	countri	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
close	JJ	close	close	close	N	O
contact	NN	contact	contact	contact	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
person	NN	person	person	person	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
.	.	.	.	.	N	O

Monitoring	VBG	monitoring	monitoring	monitor	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Tests	NNS	tests	test	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
falsely	RB	falsely	falsely	fals	N	O
negative	JJ	negative	negative	neg	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
who	WP	who	who	who	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
infection	NN	infection	infection	infect	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
,	,	,	,	,	N	O
undergo	VBP	undergo	undergo	undergo	N	O
a	DT	a	a	a	N	O
prompt	NN	prompt	prompt	prompt	N	O
and	CC	and	and	and	N	O
complete	JJ	complete	complete	complet	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
workup	NN	workup	workup	workup	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
immunocompromised	JJ	immunocompromised	immunocompromised	immunocompromis	Y	O
patient	NN	patient	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
antimicrobial	JJ	antimicrobial	antimicrobial	antimicrobi	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
.	.	.	.	.	N	O

Invasive	JJ	invasive	invasive	invas	N	O
Fungal	NNP	fungal	fungal	fungal	N	O
Infections	NNS	infections	infection	infect	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
reside	VBP	reside	reside	resid	N	O
or	CC	or	or	or	N	O
travel	VBP	travel	travel	travel	N	O
in	IN	in	in	in	N	O
regions	NNS	regions	region	region	N	O
where	WRB	where	where	where	N	O
mycoses	NNS	mycoses	mycoses	mycos	N	O
are	VBP	are	are	are	N	O
endemic	JJ	endemic	endemic	endem	N	O
,	,	,	,	,	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infection	NN	infection	infection	infect	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
suspected	VBN	suspected	suspected	suspect	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
systemic	JJ	systemic	systemic	system	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
empiric	JJ	empiric	empiric	empir	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
while	IN	while	while	while	N	O
a	DT	a	a	a	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
workup	NN	workup	workup	workup	N	O
is	VBZ	is	is	is	N	O
being	VBG	being	being	be	N	O
performed	VBN	performed	performed	perform	N	O
.	.	.	.	.	N	O

Antigen	NNP	antigen	antigen	antigen	N	O
and	CC	and	and	and	N	O
antibody	NN	antibody	antibody	antibodi	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
histoplasmosis	NN	histoplasmosis	histoplasmosis	histoplasmosi	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
negative	JJ	negative	negative	neg	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
feasible	JJ	feasible	feasible	feasibl	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
decision	NN	decision	decision	decis	N	O
to	TO	to	to	to	N	O
administer	VB	administer	administer	administ	N	O
empiric	JJ	empiric	empiric	empir	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
in	IN	in	in	in	N	O
consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
with	IN	with	with	with	N	O
expertise	NN	expertise	expertise	expertis	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
take	VB	take	take	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
both	CC	both	both	both	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
some	DT	some	some	some	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
more	JJR	more	more	more	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
control	VB	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
labeled	JJ	labeled	labeled	label	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
diseases	NNS	diseases	disease	diseas	N	O
,	,	,	,	,	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
non	RB	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
skin	JJ	skin	skin	skin	N	I-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
confidence	NN	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
0.5	CD	0.5	0.5	0.5	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
,	,	,	,	,	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
among	IN	among	among	among	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
650	CD	650	650	650	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	IN	versus	versus	versu	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
0.6	CD	0.6	0.6	0.6	N	O
(	(	(	(	(	N	O
0.1	CD	0.1	0.1	0.1	N	O
,	,	,	,	,	N	O
1.7	CD	1.7	1.7	1.7	N	O
)	)	)	)	)	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
among	IN	among	among	among	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
319	CD	319	319	319	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
size	NN	size	size	size	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
limited	JJ	limited	limited	limit	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
studies	NNS	studies	study	studi	N	O
precludes	VBP	precludes	precludes	preclud	N	O
the	DT	the	the	the	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
draw	VB	draw	draw	draw	N	O
firm	JJ	firm	firm	firm	N	O
conclusions	NNS	conclusions	conclusion	conclus	N	O
.	.	.	.	.	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
among	IN	among	among	among	N	O
children	NNS	children	child	children	N	O
,	,	,	,	,	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
young	JJ	young	young	young	N	O
adults	NNS	adults	adult	adult	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
blocking	VBG	blocking	blocking	block	N	I-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
(	(	(	(	(	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
half	PDT	half	half	half	N	O
the	DT	the	the	the	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
lymphomas	JJ	lymphomas	lymphoma	lymphoma	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	B-AdverseReaction
's	POS	's	's	's	N	O
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	I-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
cases	NNS	cases	case	case	N	O
represented	VBD	represented	represented	repres	N	O
a	DT	a	a	a	N	O
variety	NN	variety	variety	varieti	N	O
of	IN	of	of	of	N	O
different	JJ	different	different	differ	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
rare	JJ	rare	rare	rare	N	B-AdverseReaction
malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
usually	RB	usually	usually	usual	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
and	CC	and	and	and	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
usually	RB	usually	usually	usual	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
a	DT	a	a	a	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
84	CD	84	84	84	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
receiving	VBG	receiving	receiving	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
variety	NN	variety	variety	varieti	N	O
of	IN	of	of	of	N	O
sources	NNS	sources	source	sourc	N	O
including	VBG	including	including	includ	N	O
registries	NNS	registries	registry	registri	N	O
and	CC	and	and	and	N	O
spontaneous	JJ	spontaneous	spontaneous	spontan	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
reports	NNS	reports	report	report	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
all	PDT	all	all	all	N	O
the	DT	the	the	the	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
more	JJR	more	more	more	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
control	VB	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
for	IN	for	for	for	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
investigational	JJ	investigational	investigational	investig	N	O
uses	NNS	uses	us	use	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
among	IN	among	among	among	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
657	CD	657	657	657	N	O
Cimzia	NNP	cimzia	cimzia	cimzia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	B-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
among	IN	among	among	among	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
319	CD	319	319	319	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
RA	NNP	ra	ra	ra	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
)	)	)	)	)	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
three	CD	three	three	three	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
367	CD	367	367	367	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
is	VBZ	is	is	is	N	O
approximately	RB	approximately	approximately	approxim	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
expected	VBN	expected	expected	expect	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
highly	RB	highly	highly	highli	N	O
active	JJ	active	active	activ	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
.	.	.	.	.	N	O

Rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
for	IN	for	for	for	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
predict	VB	predict	predict	predict	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
when	WRB	when	when	when	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
broader	JJR	broader	broader	broader	N	O
patient	JJ	patient	patient	patient	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
that	IN	that	that	that	N	O
require	VBZ	require	require	requir	N	O
chronic	JJ	chronic	chronic	chronic	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
immunosuppressant	VB	immunosuppressant	immunosuppressant	immunosuppress	N	B-DrugClass
therapies	NNS	therapies	therapy	therapi	N	I-DrugClass
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
role	NN	role	role	role	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
hepatosplenic	JJ	hepatosplenic	hepatosplenic	hepatosplen	N	B-AdverseReaction
T	NNP	t	t	t	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
HSTCL	NNP	hstcl	hstcl	hstcl	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
rare	JJ	rare	rare	rare	N	O
type	NN	type	type	type	N	O
of	IN	of	of	of	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
that	WDT	that	that	that	N	O
has	VBZ	has	ha	ha	N	O
a	DT	a	a	a	N	O
very	RB	very	very	veri	N	O
aggressive	JJ	aggressive	aggressive	aggress	N	O
disease	NN	disease	disease	diseas	N	O
course	NN	course	course	cours	N	O
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
usually	RB	usually	usually	usual	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
reported	VBN	reported	reported	report	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
cases	NNS	cases	case	case	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
and	CC	and	and	and	N	O
young	JJ	young	young	young	N	O
adult	NN	adult	adult	adult	N	O
males	NNS	males	male	male	N	O
with	IN	with	with	with	N	O
Crohn	NNP	crohn	crohn	crohn	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
or	CC	or	or	or	N	O
ulcerative	JJ	ulcerative	ulcerative	ulcer	N	O
colitis	NN	colitis	colitis	coliti	Y	O
.	.	.	.	.	N	O

Almost	RB	almost	almost	almost	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
received	VBN	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
azathioprine	NN	azathioprine	azathioprine	azathioprin	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
mercaptopurine	NN	mercaptopurine	mercaptopurine	mercaptopurin	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
MP	NN	mp	mp	mp	N	O
)	)	)	)	)	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
at	IN	at	at	at	N	O
or	CC	or	or	or	N	O
prior	VB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
diagnosis	VB	diagnosis	diagnosis	diagnosi	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
HSTCL	NNP	hstcl	hstcl	hstcl	N	O
is	VBZ	is	is	is	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
other	JJ	other	other	other	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
using	VBG	using	using	use	N	O
a	DT	a	a	a	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
azathioprine	NN	azathioprine	azathioprine	azathioprin	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
MP	NN	mp	mp	mp	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
and	CC	and	and	and	N	O
chronic	JJ	chronic	chronic	chronic	N	B-AdverseReaction
leukemia	NN	leukemia	leukemia	leukemia	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
blocker	NN	blocker	blocker	blocker	N	I-DrugClass
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
RA	NNP	ra	ra	ra	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
indications	NNS	indications	indication	indic	N	O
.	.	.	.	.	N	O

Even	RB	even	even	even	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RA	NNP	ra	ra	ra	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
leukemia	NN	leukemia	leukemia	leukemia	Y	O
.	.	.	.	.	N	O

Periodic	JJ	periodic	periodic	period	N	O
skin	NN	skin	skin	skin	N	O
examinations	NNS	examinations	examination	examin	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
skin	JJ	skin	skin	skin	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Heart	NNP	heart	heart	heart	N	O
Failure	NN	failure	failure	failur	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
congestive	JJ	congestive	congestive	congest	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
CHF	NNP	chf	chf	chf	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
new	JJ	new	new	new	N	B-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
CHF	NNP	chf	chf	chf	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
formally	RB	formally	formally	formal	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CHF	NNP	chf	chf	chf	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CHF	NNP	chf	chf	chf	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blocker	NN	blocker	blocker	blocker	N	I-DrugClass
,	,	,	,	,	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
congestive	JJ	congestive	congestive	congest	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
CHF	NNP	chf	chf	chf	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
mortality	NN	mortality	mortality	mortal	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
CHF	NNP	chf	chf	chf	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Exercise	NN	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
them	PRP	them	them	them	N	O
carefully	RB	carefully	carefully	care	N	O
[	VB	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
could	MD	could	could	could	N	B-Factor
be	VB	be	be	be	N	O
compatible	JJ	compatible	compatible	compat	N	O
with	IN	with	with	with	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
rarely	RB	rarely	rarely	rare	N	O
following	VBG	following	following	follow	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
administration	NN	administration	administration	administr	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
serum	NN	serum	serum	serum	N	B-AdverseReaction
sickness	NN	sickness	sickness	sick	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
further	JJ	further	further	further	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
institute	JJ	institute	institute	institut	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
data	NN	data	data	data	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
using	VBG	using	using	use	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
experienced	VBN	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
towards	IN	towards	towards	toward	N	O
another	DT	another	another	anoth	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
;	:	;	;	;	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
caution	VBP	caution	caution	caution	N	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
Virus	NNP	virus	virus	viru	N	O
Reactivation	NNP	reactivation	reactivation	reactiv	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
(	(	(	(	(	N	O
HBV	NNP	hbv	hbv	hbv	N	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
chronic	JJ	chronic	chronic	chronic	N	O
carriers	NNS	carriers	carrier	carrier	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
virus	NN	virus	virus	viru	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
instances	NNS	instances	instance	instanc	N	O
,	,	,	,	,	N	O
HBV	NNP	hbv	hbv	hbv	N	B-AdverseReaction
reactivation	NN	reactivation	reactivation	reactiv	N	I-AdverseReaction
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blocker	NN	blocker	blocker	blocker	N	I-DrugClass
therapy	NN	therapy	therapy	therapi	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
reports	NNS	reports	report	report	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
receiving	VBG	receiving	receiving	receiv	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
suppress	VBP	suppress	suppress	suppress	N	O
the	DT	the	the	the	N	O
immune	NN	immune	immune	immun	N	O
system	NN	system	system	system	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
contribute	VB	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
HBV	NNP	hbv	hbv	hbv	N	B-AdverseReaction
reactivation	NN	reactivation	reactivation	reactiv	N	I-AdverseReaction
.	.	.	.	.	N	O

Test	NN	test	test	test	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
test	VBP	test	test	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
with	IN	with	with	with	N	O
expertise	NN	expertise	expertise	expertis	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

Adequate	NNP	adequate	adequate	adequ	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
or	CC	or	or	or	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
carriers	NNS	carriers	carrier	carrier	N	O
of	IN	of	of	of	N	O
HBV	NNP	hbv	hbv	hbv	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
viral	JJ	viral	viral	viral	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
prevent	VB	prevent	prevent	prevent	N	O
HBV	NNP	hbv	hbv	hbv	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
carriers	NNS	carriers	carrier	carrier	N	O
of	IN	of	of	of	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
require	VB	require	require	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
clinical	JJ	clinical	clinical	clinic	N	O
and	CC	and	and	and	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
active	JJ	active	active	activ	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
throughout	IN	throughout	throughout	throughout	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
following	VBG	following	following	follow	N	O
termination	NN	termination	termination	termin	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
HBV	NNP	hbv	hbv	hbv	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
effective	JJ	effective	effective	effect	N	O
anti	NNS	anti	anti	anti	N	O
-	:	-	-	-	N	O
viral	JJ	viral	viral	viral	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
supportive	JJ	supportive	supportive	support	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
resuming	VBG	resuming	resuming	resum	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
after	IN	after	after	after	N	O
HBV	NNP	hbv	hbv	hbv	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
is	VBZ	is	is	is	N	O
controlled	VBN	controlled	controlled	control	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
exercise	NN	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
considering	VBG	considering	considering	consid	N	O
resumption	NN	resumption	resumption	resumpt	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
situation	NN	situation	situation	situat	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Neurologic	NNP	neurologic	neurologic	neurolog	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
member	NN	member	member	member	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	O
onset	NN	onset	onset	onset	N	O
or	CC	or	or	or	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
radiographic	JJ	radiographic	radiographic	radiograph	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
central	JJ	central	central	central	N	B-AdverseReaction
nervous	JJ	nervous	nervous	nervou	Y	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
demyelinating	VBG	demyelinating	demyelinating	demyelin	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
multiple	JJ	multiple	multiple	multipl	N	B-AdverseReaction
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
demyelinating	VBG	demyelinating	demyelinating	demyelin	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

Exercise	NN	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
considering	VBG	considering	considering	consid	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	NN	existing	existing	exist	N	O
or	CC	or	or	or	N	O
recent	JJ	recent	recent	recent	N	O
-	:	-	-	-	N	O
onset	JJ	onset	onset	onset	N	O
central	JJ	central	central	central	N	O
or	CC	or	or	or	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
demyelinating	VBG	demyelinating	demyelinating	demyelin	N	O
disorders	NNS	disorders	disorder	disord	N	O
.	.	.	.	.	N	O

Rare	JJ	rare	rare	rare	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
optic	JJ	optic	optic	optic	N	B-AdverseReaction
neuritis	NN	neuritis	neuritis	neuriti	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NNS	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Hematological	JJ	hematological	hematological	hematolog	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Rare	JJ	rare	rare	rare	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
aplastic	JJ	aplastic	aplastic	aplast	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
hematologic	NN	hematologic	hematologic	hematolog	N	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
medically	RB	medically	medically	medic	N	B-Severity
significant	JJ	significant	significant	signific	N	I-Severity
cytopenia	NN	cytopenia	cytopenia	cytopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
infrequently	RB	infrequently	infrequently	infrequ	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
to	TO	to	to	to	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
remains	VBZ	remains	remains	remain	N	O
unclear	JJ	unclear	unclear	unclear	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
no	DT	no	no	no	N	O
high	JJ	high	high	high	N	O
risk	NN	risk	risk	risk	N	O
group	NN	group	group	group	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
,	,	,	,	,	N	O
exercise	VBP	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
ongoing	JJ	ongoing	ongoing	ongo	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
significant	JJ	significant	significant	signific	N	O
hematologic	JJ	hematologic	hematologic	hematolog	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
develop	VBP	develop	develop	develop	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
dyscrasias	NN	dyscrasias	dyscrasia	dyscrasia	N	O
or	CC	or	or	or	N	O
infection	NN	infection	infection	infect	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
bruising	NN	bruising	bruising	bruis	Y	O
,	,	,	,	,	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
,	,	,	,	,	N	O
pallor	NN	pallor	pallor	pallor	Y	O
)	)	)	)	)	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
significant	JJ	significant	significant	signific	N	O
hematologic	NN	hematologic	hematologic	hematolog	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Biological	NNP	biological	biological	biolog	N	O
Disease	NNP	disease	disease	diseas	N	O
-	:	-	-	-	N	O
Modifying	VBG	modifying	modifying	modifi	N	O
Antirheumatic	JJ	antirheumatic	antirheumatic	antirheumat	N	O
Drugs	NNP	drugs	drug	drug	N	O
(	(	(	(	(	N	O
Biological	NNP	biological	biological	biolog	N	O
DMARDs	NNP	dmards	dmards	dmard	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
anakinra	NN	anakinra	anakinra	anakinra	N	O
(	(	(	(	(	N	O
an	DT	an	an	an	N	O
interleukin	NN	interleukin	interleukin	interleukin	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
antagonist	NN	antagonist	antagonist	antagonist	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
another	DT	another	another	anoth	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blocker	NN	blocker	blocker	blocker	N	O
,	,	,	,	,	N	O
etanercept	NN	etanercept	etanercept	etanercept	N	B-DrugClass
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	O
added	JJ	added	added	ad	N	O
benefit	NN	benefit	benefit	benefit	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
etanercept	VB	etanercept	etanercept	etanercept	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TNF	NNP	tnf	tnf	tnf	N	B-DrugClass
blockers	NNS	blockers	blocker	blocker	N	I-DrugClass
with	IN	with	with	with	N	O
abatacept	NN	abatacept	abatacept	abatacept	N	O
and	CC	and	and	and	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
nature	NN	nature	nature	natur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
seen	VBN	seen	seen	seen	N	O
with	IN	with	with	with	N	O
this	DT	this	this	thi	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
similar	JJ	similar	similar	similar	N	O
toxicities	NNS	toxicities	toxicity	toxic	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
result	VB	result	result	result	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
combination	NN	combination	combination	combin	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
biological	JJ	biological	biological	biolog	N	O
DMARDs	NNP	dmards	dmards	dmard	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Autoimmunity	NN	autoimmunity	autoimmunity	autoimmun	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
formation	NN	formation	formation	format	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
autoantibodies	NNS	autoantibodies	autoantibody	autoantibodi	N	I-AdverseReaction
and	CC	and	and	and	N	O
rarely	RB	rarely	rarely	rare	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
lupus	JJ	lupus	lupus	lupu	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
lupus	JJ	lupus	lupus	lupu	N	O
-	:	-	-	-	N	O
like	IN	like	like	like	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
following	VBG	following	following	follow	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Immunizations	NNS	immunizations	immunization	immun	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
may	MD	may	may	may	N	O
receive	VB	receive	receive	receiv	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
,	,	,	,	,	N	O
except	IN	except	except	except	N	O
for	IN	for	for	for	N	O
live	JJ	live	live	live	N	O
or	CC	or	or	or	N	O
live	JJ	live	live	live	N	O
attenuated	VBN	attenuated	attenuated	attenu	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
data	NN	data	data	data	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
live	VB	live	live	live	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
secondary	JJ	secondary	secondary	secondari	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
by	IN	by	by	by	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rheumatoid	JJ	rheumatoid	rheumatoid	rheumatoid	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
difference	NN	difference	difference	differ	N	O
was	VBD	was	wa	wa	N	O
detected	VBN	detected	detected	detect	N	O
in	IN	in	in	in	N	O
antibody	NN	antibody	antibody	antibodi	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
vaccine	VB	vaccine	vaccine	vaccin	N	O
between	IN	between	between	between	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
placebo	VB	placebo	placebo	placebo	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
pneumococcal	JJ	pneumococcal	pneumococcal	pneumococc	N	O
polysaccharide	NN	polysaccharide	polysaccharide	polysaccharid	N	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
and	CC	and	and	and	N	O
influenza	JJ	influenza	influenza	influenza	Y	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
were	VBD	were	were	were	N	O
administered	VBN	administered	administered	administ	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
.	.	.	.	.	N	O

Similar	JJ	similar	similar	similar	N	O
proportions	NNS	proportions	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBN	developed	developed	develop	N	O
protective	JJ	protective	protective	protect	N	O
levels	NNS	levels	level	level	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
between	IN	between	between	between	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
placebo	VB	placebo	placebo	placebo	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
and	CC	and	and	and	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
methotrexate	NN	methotrexate	methotrexate	methotrex	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
humoral	JJ	humoral	humoral	humor	N	O
response	NN	response	response	respons	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O

Since	IN	since	since	sinc	N	O
TNF	NNP	tnf	tnf	tnf	N	O
mediates	VBZ	mediates	mediates	mediat	N	O
inflammation	NN	inflammation	inflammation	inflamm	Y	O
and	CC	and	and	and	N	O
modulates	VBZ	modulates	modulates	modul	N	O
cellular	JJ	cellular	cellular	cellular	N	O
immune	NN	immune	immune	immun	N	O
responses	NNS	responses	response	respons	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
exists	VBZ	exists	exists	exist	N	O
for	IN	for	for	for	N	O
TNF	NNP	tnf	tnf	tnf	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
affect	VB	affect	affect	affect	N	O
host	NN	host	host	host	N	O
defenses	NNS	defenses	defense	defens	N	O
against	IN	against	against	against	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
impact	NN	impact	impact	impact	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
and	CC	and	and	and	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
active	JJ	active	active	activ	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
chronic	JJ	chronic	chronic	chronic	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
fully	RB	fully	fully	fulli	N	O
understood	JJ	understood	understood	understood	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
CIMZIA	NNP	cimzia	cimzia	cimzia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
formally	RB	formally	formally	formal	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

